nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2007 | Editorial

Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

verfasst von: Sandip Basu, Abass Alavi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Excerpt

With the growing use of FDG-PET, there is an increasing body of literature reporting non-specific FDG accumulation in a wide spectrum of anatomical variants and physiological processes as well as in several benign pathologies. This observation has led to active research with regard to the utility of this modality in assessing patients with suspected or known infection or inflammatory disorders. However, there is growing interest in improving the specificity of the technique in patients with cancer. Efforts are being made to modify the acquisition and analysis of image data for FDG-PET and to develop new tracers that have superior specificity. …

Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–50.PubMed

Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164–7.PubMed

Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996;17:890–4.PubMedCrossRef

Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441–4.PubMed

Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345–8.PubMedCrossRef

Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual-time-point ¹⁸F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871–5.PubMed

Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with¹⁸F-FDG PET. J Nucl Med 2005;46:1819–24.PubMed

Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, et al. Dual time point¹⁸F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006;47:1440–6.PubMed

Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226–30.PubMedCrossRef

10.

Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time-point¹⁸F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006;47:633–8.PubMed

11.

Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed ¹⁸F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775–83.PubMed

12.

Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, et al.¹⁸F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 2004;45:1653–9.PubMed

13.

Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [¹⁸F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154–61.PubMed

14.

Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to³H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996;23:533–41.PubMedCrossRef

15.

Suzuki S, Toyota T, Suzuki H, Goto Y. Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase. Arch Biochem Biophys 1984;235:418–26.PubMedCrossRef

16.

Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308–12.PubMed

17.

Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of ¹⁸FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22–30.PubMedCrossRef

18.

Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point ¹⁸F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412–7.PubMed

19.

Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer’s disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993;34:1681–7.PubMed

20.

Kohn MI, Tanna NK, Herman GT, Resnick SM, Mozley PD, Gur RE, et al. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology 1991;178:115–22.PubMed

21.

Baete K, Nuyts J, Van Laere K, Van Paesschen W, Ceyssens S, De Ceuninck L, et al. Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. NeuroImage 2004;23:305–17.PubMedCrossRef

22.

Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 2004;45:192–201.PubMed

23.

Aston JAD, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN. Positron emission tomography partial volume correction: estimation and algorithms. J Cereb Blood Flow Metab 2002;22:1019–34.PubMedCrossRef

24.

Weber W, Young C, Abdel-Dayem HM, Sfakianakis G, Weir GJ, Swaney CM, et al. Assessment of pulmonary lesions with¹⁸F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999;40:574–8.PubMed

25.

Lubberink M, Tolmachev V, Widstrom C, Bruskin A, Lundqvist H, Westlin JE. 110mIn-DTPA-D-Phe¹-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002;43:1391–7.PubMed

26.

Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639–47.PubMedCrossRef

27.

Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997;38:1186–91.PubMed

Titel: Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?
verfasst von: Sandip Basu
Abass Alavi
Publikationsdatum: 01.10.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0467-5

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2007

Diagnosis of endoneural sciatic nerve invasion by uterine cervical epidermoid cancer using [18F]FDG-PET/CT

Negative MIBI thyroid scans exclude differentiated and medullary thyroid cancer in 100% of patients with hypofunctioning thyroid nodules

Positron detection for the intraoperative localisation of cancer deposits

Synthesis and initial evaluation of [11C](R)-RWAY in monkey—a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET

Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract

Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology